The Life Sciences Report Examines How 3D Signatures' TeloView Can Diagnose Alzheimer's with a Cheek Swab

SAN FRANCISCO, CA--(Marketwired - March 31, 2017) - With a swab taken from the inside of a patient's cheek, 3D Signatures Inc.'s (TSX VENTURE: DXD) (OTCQB: TDSGF) TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and also to assess whether the disease is manifesting in a mild, moderate or severe form.

Included in this article is: 3D Signatures Inc.

The company reported the results of its second clinical study of the TeloView platform in the degenerative brain disease in a March 21 press release. The results of the study have been accepted for publication in the Journal of Alzheimer's Disease.

Because the TeloView Alzheimer's test is both accurate and minimally invasive, it represents a disruptive diagnostic and prognostic tool for a disease that affects five million Americans over the age of 65, according to the company.

In the press release, Dr. Sabine Mai, 3D Signatures' cofounder and principal inventor, stated that, at present, Alzheimer's disease (AD) "is only confirmed postmortem pathologically. There is a significant need for an accurate, non-invasive biomarker that can diagnose AD and indicate disease progression, and we believe TeloView has the potential to answer that important call."

"As we understand it there's more than 1,000 drugs in development and working toward FDA approval right now for Alzheimer's and there's no test to tell if they work," said Jason Flowerday, 3D Signatures' CEO. "There's a lot of resources being devoted to finding therapies that are effective, and we're trying to develop a tool that will enable companies to identify better drugs, select appropriate patients for trials, monitor patients during trials and ultimately get those drugs to market."

If the 3D Signatures' platform proves its utility in additional clinical studies, company representatives told The Life Sciences Report the technology could be easily adopted by large pharma and biotech companies looking to ensure patients enrolled in clinical trials in Alzheimer's drug development truly have the disease, and could also be an accurate and cost-effective way to monitor progression of the disease in those drug trials.

The company is "exploring opportunities to expand the scope of its AD related work with further clinical studies and to fund that work through non-dilutive or independent financing arrangements, such as a joint venture," the press release states.